BACKGROUND: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. PATIENTS AND METHODS: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. RESULTS: Median number of therapeutic lines before accrual was 4. Median interval time between last cycle of first cetuximab-based therapy and first cycle of the retreatment was 6 months. Overall response rate was 53.8\% with 19 partial responses (48.7\%) and 2 complete responses (5.1\%). Disease stabilization was obtained in 35.9\% of patients and progression in four patients (10.2\%). Median progression-free survival was 6.6 months. The correlation between skin toxicity during first cetuximab therapy and during cetuximab rechallenge was significant (P = 0.01). CONCLUSION: Rechallenge with the same cetuximab-based therapy may achieve a new important clinical benefit further delaying the progression of disease and improving the therapeutic options.

Background: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and methods: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. Results: Median number of therapeutic lines before accrual was 4. Median interval time between last cycle of first cetuximab-based therapy and first cycle of the retreatment was 6 months. Overall response rate was 53.8% with 19 partial responses (48.7%) and 2 complete responses (5.1%). Disease stabilization was obtained in 35.9% of patients and progression in four patients (10.2%). Median progression-free survival was 6.6 months. The correlation between skin toxicity during first cetuximab therapy and during cetuximab rechallenge was significant (P = 0.01). Conclusion: Rechallenge with the same cetuximab-based therapy may achieve a new important clinical benefit further delaying the progression of disease and improving the therapeutic options. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? / Santini, Davide; Vincenzi, B.; Addeo, R.; Garufi, C.; Masi, G.; Scartozzi, Mario; Mancuso, Alessia; Frezza, A. M.; Venditti, O.; Imperatori, M.; Schiavon, G.; Bronte, G.; Cicero, G.; Recine, F.; Maiello, E.; Cascinu, Stefano; Russo, A.; Falcone, VINCENZO ALESSIO; Tonini, G.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:9(2012), pp. 2313-2318. [10.1093/annonc/mdr623]

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

SANTINI, DAVIDE;SCARTOZZI, MARIO;MANCUSO, ALESSIA;CASCINU, Stefano;FALCONE, VINCENZO ALESSIO;
2012

Abstract

BACKGROUND: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. PATIENTS AND METHODS: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. RESULTS: Median number of therapeutic lines before accrual was 4. Median interval time between last cycle of first cetuximab-based therapy and first cycle of the retreatment was 6 months. Overall response rate was 53.8\% with 19 partial responses (48.7\%) and 2 complete responses (5.1\%). Disease stabilization was obtained in 35.9\% of patients and progression in four patients (10.2\%). Median progression-free survival was 6.6 months. The correlation between skin toxicity during first cetuximab therapy and during cetuximab rechallenge was significant (P = 0.01). CONCLUSION: Rechallenge with the same cetuximab-based therapy may achieve a new important clinical benefit further delaying the progression of disease and improving the therapeutic options.
23
9
2313
2318
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? / Santini, Davide; Vincenzi, B.; Addeo, R.; Garufi, C.; Masi, G.; Scartozzi, Mario; Mancuso, Alessia; Frezza, A. M.; Venditti, O.; Imperatori, M.; Schiavon, G.; Bronte, G.; Cicero, G.; Recine, F.; Maiello, E.; Cascinu, Stefano; Russo, A.; Falcone, VINCENZO ALESSIO; Tonini, G.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:9(2012), pp. 2313-2318. [10.1093/annonc/mdr623]
Santini, Davide; Vincenzi, B.; Addeo, R.; Garufi, C.; Masi, G.; Scartozzi, Mario; Mancuso, Alessia; Frezza, A. M.; Venditti, O.; Imperatori, M.; Schiavon, G.; Bronte, G.; Cicero, G.; Recine, F.; Maiello, E.; Cascinu, Stefano; Russo, A.; Falcone, VINCENZO ALESSIO; Tonini, G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1079306
Citazioni
  • ???jsp.display-item.citation.pmc??? 54
  • Scopus 136
  • ???jsp.display-item.citation.isi??? 119
social impact